216 related articles for article (PubMed ID: 23396091)
41. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
Skaricic D; Traube C; De B; Joh J; Boyer J; Crystal RG; Worgall S
Virology; 2008 Aug; 378(1):79-85. PubMed ID: 18556039
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
Gutfraind A; Galvani AP; Meyers LA
JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
[TBL] [Abstract][Full Text] [Related]
43. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
44. Palivizumab in the prevention of respiratory syncytial virus disease.
Krilov LR
Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675
[TBL] [Abstract][Full Text] [Related]
45. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
Feltes TF; Sondheimer HM
Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients.
Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Ferlic-Stark LL; Patel KD; Piedra FA; Shah DP; Chemaly RF; Piedra PA
J Infect Dis; 2018 Mar; 217(8):1247-1256. PubMed ID: 29365155
[TBL] [Abstract][Full Text] [Related]
47. Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis.
Maas BM; Lommerse J; Plock N; Railkar RA; Cheung SYA; Caro L; Chen J; Liu W; Zhang Y; Huang Q; Gao W; Qin L; Meng J; Witjes H; Schindler E; Guiastrennec B; Bellanti F; Spellman DS; Roadcap B; Kalinova M; Fok-Seang J; Catchpole AP; Espeseth AS; Stoch SA; Lai E; Vora KA; Aliprantis AO; Sachs JR
EBioMedicine; 2021 Nov; 73():103651. PubMed ID: 34775220
[TBL] [Abstract][Full Text] [Related]
48. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
49. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.
Jacobino SR; Nederend M; Reijneveld JF; Augustijn D; Jansen JHM; Meeldijk J; Reiding KR; Wuhrer M; Coenjaerts FEJ; Hack CE; Bont LJ; Leusen JHW
MAbs; 2018 Apr; 10(3):453-462. PubMed ID: 29553863
[TBL] [Abstract][Full Text] [Related]
50. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
51. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
52. Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response.
Borochova K; Niespodziana K; Focke-Tejkl M; Hofer G; Keller W; Valenta R
Sci Rep; 2021 Feb; 11(1):3551. PubMed ID: 33574352
[TBL] [Abstract][Full Text] [Related]
53. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
Detalle L; Stohr T; Palomo C; Piedra PA; Gilbert BE; Mas V; Millar A; Power UF; Stortelers C; Allosery K; Melero JA; Depla E
Antimicrob Agents Chemother; 2016 Jan; 60(1):6-13. PubMed ID: 26438495
[TBL] [Abstract][Full Text] [Related]
54. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.
Jones HG; Ritschel T; Pascual G; Brakenhoff JPJ; Keogh E; Furmanova-Hollenstein P; Lanckacker E; Wadia JS; Gilman MSA; Williamson RA; Roymans D; van 't Wout AB; Langedijk JP; McLellan JS
PLoS Pathog; 2018 Mar; 14(3):e1006935. PubMed ID: 29509814
[TBL] [Abstract][Full Text] [Related]
55. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
Groothuis JR; Nishida H
Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
[TBL] [Abstract][Full Text] [Related]
56. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
Groothuis JR; Hoopes JM; Hemming VG
Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
[TBL] [Abstract][Full Text] [Related]
57. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
Brady T; Cayatte C; Roe TL; Speer SD; Ji H; Machiesky L; Zhang T; Wilkins D; Tuffy KM; Kelly EJ
Front Immunol; 2023; 14():1283120. PubMed ID: 37901217
[TBL] [Abstract][Full Text] [Related]
58. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
59. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics).
Canfield SD; Simoes EA
Pediatr Ann; 1999 Aug; 28(8):507-14. PubMed ID: 10483596
[No Abstract] [Full Text] [Related]
60. A review of palivizumab and emerging therapies for respiratory syncytial virus.
Shadman KA; Wald ER
Expert Opin Biol Ther; 2011 Nov; 11(11):1455-67. PubMed ID: 21831008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
